Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet™ as a Potential Treatment for Bone Metastases
Press Release Provided by Zetagen
- Peer-reviewed case report examines use of investigational treatment in a Stage 4 metastatic breast cancer patient.
- Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture.
- ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.
- ZetaMet™ was granted FDA Breakthrough Device Designation in 2021 and is in Phase 2a clinical trials for treatment of metastatic breast cancer lesions to bone as part of advanced stage cancer therapy.
SYRACUSE, N.Y.--(BUSINESS WIRE)--Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.
“Recently, I had the opportunity to spend some time with this patient. I will always remember what she said to me: ‘thank you for giving me more time’”
This case study, entitled Treating Bone Metastases with Local Therapy in a Breast Cancer Patient Resulted in Decrease Pain and Prevented Fracture, demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture in a patient living with Stage 4 breast cancer being treated with ZetaMet™.
To view the publication via open access, go to: https://www.futuremedicine.com/doi/10.2217/pmt-2023-0069
ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.